Roche doubles down on Poseida
A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.
ASH 2024 preview – CD19 back on the agenda
Astra squares up to Merck's Curon deal, while Novartis and Galapagos face off in fast-manufactured Car-T.
The month ahead: November’s upcoming events
Conferences ramp up, and ASH abstracts near.
Pfizer takes on Merck in a new checkpoint
Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.
